<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686359</url>
  </required_header>
  <id_info>
    <org_study_id>P081106</org_study_id>
    <nct_id>NCT02686359</nct_id>
  </id_info>
  <brief_title>Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)</brief_title>
  <acronym>OPIODYN</acronym>
  <official_title>Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pasteur</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If epidemiological studies indicate relatively low prevalence reported in the general&#xD;
      population, idiopathic burning mouth syndrome (BMS) is a common condition among certain&#xD;
      groups of the population: 30% of menopausal women experience oral burning to varying degrees&#xD;
      . Despite significant progress made in recent years, in understanding the physiopathogeny,&#xD;
      treatment options remain limited and disappointing,resulting in an impairment of the quality&#xD;
      of life. Given the chronic nature of idiopathic burning mouth syndrome, the need to identify&#xD;
      the causes and effective treatment modalities for subjects suffering is essential.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic burning mouth syndrome (BMS) is a chronic orofacial pain condition in which the&#xD;
      pain is felt as intense, located on the tongue and the oral mucosa with no known cause. The&#xD;
      pain may last for years and present treatments are of little effect. BMS is primarily a&#xD;
      feminine disease, affecting women during or following menopause, suggesting an etiopathogenic&#xD;
      role of the sexual hormones potentiating a local salivary factor. An anxiodepressive&#xD;
      component is often associated with the disease. Recently, a molecule named opiorphin has been&#xD;
      identified in human saliva. In animals, this molecule has shown potent analgesic properties&#xD;
      comparable to those of morphine. The hypothesis of the investigators is that this molecule is&#xD;
      in lower quantity in the saliva of persons suffering BMS and that this decrease causes oral&#xD;
      burning sensations.&#xD;
&#xD;
      The main objective of the study is to test the hypothesis of a decrease of opiorphin levels&#xD;
      in the saliva of patients suffering from primary BMS compared to a group of control subjects.&#xD;
      The main judgment criteria is the level of salivary opiorphin in ng/mL.&#xD;
&#xD;
      The proposed study is a multicentric, simple blinded case controlled study. The investigators&#xD;
      will collect the data from 21 primary BMS patients and 21 control subjects matched in sex,&#xD;
      age, and hormonal status (menopause). The alpha risk is 0.5% and the power of the study is&#xD;
      90%.&#xD;
&#xD;
      Criteria for inclusion : BMS patients will be suffering for more than 4 months from burning&#xD;
      pain in the tongue or oral mucosa with no organic trouble detectable by anamnesis, clinical&#xD;
      evaluation and biological testing.&#xD;
&#xD;
      The design of the study includes three sessions for all subject of both groups; the maximum&#xD;
      duration of participation for a subject is 8 weeks and the total duration of the study is 24&#xD;
      months There are two investigation centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>opiorphin levels in saliva</measure>
    <time_frame>Day 30</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>opiorphin levels in blood</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary levels in urine</measure>
    <time_frame>Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Burning Mouth Syndrome</condition>
  <arm_group>
    <arm_group_label>Burning Mouth Syndrome Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>saliva, blood and urinary samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>saliva, blood and urinary samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sample</intervention_name>
    <arm_group_label>Burning Mouth Syndrome Patients</arm_group_label>
    <arm_group_label>controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Burning Mouth Syndrome&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Sensation of pain in the oral mucosa, meeting the diagnostic criteria for BMS&#xD;
             (Bergdahl and Anneroth, 1993, Scala 2003)&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Healthy volunteers&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Patient age (+/- 5 years), sex and hormonal status (menopause or not for women)&#xD;
             matched with a Burning Mouth Syndrome patient&#xD;
&#xD;
          -  Signature of informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dental or periodontal pain during the month before the visit&#xD;
&#xD;
          -  General pathology likely to cause mouth pain (diabetes, lupus, shingles, gastric&#xD;
             reflux, allergies ...)&#xD;
&#xD;
          -  Chronic Orofacial pain other than Burning Mouth Syndrome&#xD;
&#xD;
          -  Treatment with a molecule able to induce oral burning sensations (anti-VEGF,&#xD;
             neuroleptics, IEC angiotensin II ...)&#xD;
&#xD;
          -  Participation concomitantly in biomedical research&#xD;
&#xD;
          -  No affiliation to a social protection system&#xD;
&#xD;
          -  Taste disorder other than a dysgeusia linked to Burning Mouth Syndrome&#xD;
&#xD;
          -  Inability to understand the information note and sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>physiology</keyword>
  <keyword>pain</keyword>
  <keyword>analgesia</keyword>
  <keyword>saliva</keyword>
  <keyword>opiorphin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burning Mouth Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

